| HOME >> BIOLOGY >> TECHNOLOGY |
WEIFANG, China, Nov. 10 /Xinhua-PRNewswire-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the Company"), a leading manufacturer and distributor of high-quality, pharmaceutical grade glucose products in China, today announced that it will issue financial results for the three months ended September 30, 2008 after the close of the stock market on Thursday, November 13, 2008. Management will conduct a conference call on Friday, November 14, 2008 at 9:00 A.M. Eastern Standard Time to discuss these results. A question and answer session will follow management's presentation.
Mr. Qingtai Liu (Chief Executive Officer), Ms. Yiru Melody Shi (CFO), and Ms. Michelle Wang (Investor Relations Manager) will be the primary speakers on the call.
A live webcast of the conference call will be available on the Investor Relations page of Shengtai Pharmaceutical's web site at http://www.shengtaipharmaceutical.com . Please visit the Web site at least 15 minutes early to register for the webcast and download any necessary audio software.
To participate, please call the following numbers ten minutes before the call start time:
Phone Number: +1-877-407-8035 (North America)
Phone Number: +1-201-689-8035 (International)
A replay of the call will be available through Friday, November 21,
2008, at 11:59 P.M. Eastern Standard Time. For the replay, please call:
Phone Number: +1-877-660-6853 (North America)
Phone Number: +1-201-612-7415 (International)
Account Number: 286
Conference ID Number: 302820
About Shengtai Pharmaceutical, Inc.
Shengtai Pharmaceutical, Inc. through its wholly owned subsidiary, Shengtai Holding, Inc. (SHI), a New Jersey corporation, and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a leading manufacturer and supplier of pharmaceutical grade glucose used for medical purposes. It also manufactures and supplies glucose and cornstarch products to the food, beverage and industrial production industries in China. For more information about Shengtai Pharmaceutical, Inc., please visit http://www.shengtaipharmaceutical.com .
Safe Harbor Statement
Certain statements in this press release and oral statements made by
the Company constitute forward-looking statements for purposes of the safe
harbor provisions under The Private Securities Litigation Reform Act of
1995. These statements include, without limitation, statements regarding
our ability to prepare the Company for growth, the Company's planned
capacity expansion in 2008 and predictions and guidance relating to the
Company's future financial performance. We have based these forward-looking
statements largely on our current expectations and projections about future
events and financial trends that we believe may affect our financial
condition, results of operations, business strategy and financial needs,
but they involve risks and uncertainties that could cause actual results to
differ materially from those in the forward-looking statements, which may
include, but are not limited to, such factors as unanticipated changes in
product demand especially in the pharmaceutical industry, pricing and
demand trends for the Company's products, changes to government
regulations, risk associated with operation of the Company's new
facilities, risk associated with large-scale implementation of the
Company's business plan, the ability to attract new customers, ability to
increase its product's applications, cost of raw materials, downturns in
the Chinese economy, and other information detailed from time to time in
the Company's filings and future filings with the United States Securities
and Exchange Commission. Investors are urged to consider these factors
carefully in evaluating the forward-looking statements herein and are
cautioned not to place undue reliance on such forward-looking statements,
which are qualified in their entirety by this cautionary statement. The
forward-looking statements made herein speak only as of the date of this
press release and the Company undertakes no duty to update any
forward-looking statement to conform the statement to actual results or
changes in the Company's expectations.
For further information, please contact:
Shengtai Pharmaceutical, Inc.
Ms. Yiru Melody Shi
Chief Financial Officer
Tel: +1-949-468-7078
Email: shengtaicfo@hotmail.com
Grayling Global
Eddie Cheung
Investor Relations
Tel: +1-646-284-9414
Email: echeung@hfgcg.com
'/>"/>
| SOURCE Shengtai Pharmaceutical, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related biology technology :
1. Shengtai Pharmaceutical Completes Factory Improvements Resulting in Operational and Environmental Benefits
2. Shengtai Pharmaceutical Retains Grayling Global As Investor Relations Counsel
3. Shengtai Pharmaceutical, Inc. Appoints New CFO
4. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
5. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
6. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
7. Idenix Pharmaceuticals to Present at Deutsche Banks 2008 Biotech Boston Confab
8. Simcere Pharmaceutical Group to Participate in Morgan Stanley Seventh Annual Asia Pacific Summit 2008
9. Critical Pharmaceuticals Raise GBP650K
10. WellSpring Pharmaceutical Corp. Announces Hire of Wayne Miller as Vice President, Sales & Marketing, Consumer Brands
11. Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |